← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

VALN logoValneva SE(VALN)Earnings, Financials & Key Ratios

VALN•NASDAQ
$5.41
$470M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryVaccines and Infectious Disease
AboutValneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.Show more
  • Revenue$170M+10.3%
  • EBITDA$33M+151.0%
  • Net Income-$12M+87.9%
  • EPS (Diluted)-0.17+88.4%
  • Gross Margin41.89%+21.9%
  • EBITDA Margin19.41%+146.3%
  • Operating Margin7.86%+114.7%
  • Net Margin-7.22%+89.1%
  • ROE-7.91%+86.4%
  • ROIC4.54%+110.8%
  • Debt/Equity1.19-26.7%
  • Interest Coverage0.56+115.8%
Technical→

VALN Key Insights

Valneva SE (VALN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 5 (bottom 5%)
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

VALN Price & Volume

Valneva SE (VALN) stock price & volume — 10-year historical chart

Loading chart...

VALN Growth Metrics

Valneva SE (VALN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years16.47%
5 Years6.09%
3 Years-21.31%
TTM13.48%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-1277.19%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-907.69%

Return on Capital

10 Years-11.93%
5 Years-17.88%
3 Years-16.73%
Last Year3.88%

VALN Recent Earnings

Valneva SE (VALN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Mar 16, 2026
EPS
$0.68
Est $0.17
-293.1%
Revenue
$55M
Est $52M
+5.8%
Q4 2025
Nov 20, 2025
EPS
$0.61
Est $0.30
-103.3%
Revenue
$34M
Est $49M
-29.5%
Q3 2025
Aug 12, 2025
EPS
$0.16
Est $0.27
+40.7%
Revenue
$57M
Est $39M
+45.5%
Q2 2025
May 7, 2025
EPS
$0.13
Est $0.31
+58.1%
Revenue
$54M
Est $44M
+21.3%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 16, 2026
$0.68vs $0.17-293.1%
$55Mvs $52M+5.8%
Q4 2025Nov 20, 2025
$0.61vs $0.30-103.3%
$34Mvs $49M-29.5%
Q3 2025Aug 12, 2025
$0.16vs $0.27+40.7%
$57Mvs $39M+45.5%
Q2 2025May 7, 2025
$0.13vs $0.31+58.1%
$54Mvs $44M+21.3%
Based on last 12 quarters of dataView full earnings history →

VALN Peer Comparison

Valneva SE (VALN) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
NVAX logoNVAXNovavax, Inc.Direct Competitor1.53B9.363.6964.69%-14.73%
DYAI logoDYAIDyadic International, Inc.Direct Competitor27.51M0.76-3.8020.58%-279.56%-281.83%2.05
IBRX logoIBRXImmunityBio, Inc.Direct Competitor8.25B8.38-13.5222.71%-422.28%
SIGA logoSIGASIGA Technologies, Inc.Direct Competitor336.57M4.7014.24-31.8%24.64%0%0
PFE logoPFEPfizer Inc.Product Competitor150.77B26.5119.49-1.65%11.83%8.34%0.78
MRK logoMRKMerck & Co., Inc.Product Competitor280.48B113.5615.601.18%28.12%36.14%0.96
GSK logoGSKGSK plcProduct Competitor101.62B50.536.694.11%19.19%31.48%1.11
SNY logoSNYSanofiProduct Competitor105.71B43.7718.375.49%16.72%10.78%0.30

Compare VALN vs Peers

Valneva SE (VALN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVAX

Most directly comparable listed peer for VALN.

Scale Benchmark

vs MRK

Larger-name benchmark to compare VALN against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVAX, DYAI, IBRX, SIGA

VALN Income Statement

Valneva SE (VALN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Sales/Revenue94.06M105.29M113.03M126.2M110.32M348.08M361.3M153.71M169.58M179.91M
Revenue Growth %20.04%11.94%7.35%11.64%-12.58%215.52%3.8%-57.46%10.32%13.48%
Cost of Goods Sold43.08M45.98M43.43M49.97M54.3M187.92M324.44M100.88M98.54M98.3M
COGS % of Revenue45.8%43.67%38.42%39.6%49.22%53.99%89.8%65.63%58.11%-
Gross Profit
50.99M▲ 0%
59.31M▲ 16.3%
69.6M▲ 17.4%
76.23M▲ 9.5%
56.02M▼ 26.5%
160.16M▲ 185.9%
36.86M▼ 77.0%
52.84M▲ 43.3%
71.04M▲ 34.5%
81.61M▲ 0%
Gross Margin %54.2%56.33%61.58%60.4%50.78%46.01%10.2%34.37%41.89%45.36%
Gross Profit Growth %62.39%16.33%17.35%9.52%-26.51%185.91%-76.98%43.34%34.45%-
Operating Expenses93.43M63.27M63.34M74.23M111.13M221.56M150.31M134.92M57.71M156.44M
OpEx % of Revenue99.33%60.09%56.03%58.82%100.73%63.65%41.6%87.78%34.03%-
Selling, General & Admin31.05M33.42M48.04M42.54M45.52M71.25M57.58M96.55M95.11M84.97M
SG&A % of Revenue33.01%31.74%42.5%33.71%41.26%20.47%15.94%62.81%56.08%-
Research & Development24.59M23.36M12.19M37.88M84.45M173.28M104.92M59.89M74.14M85.31M
R&D % of Revenue26.14%22.18%10.79%30.02%76.55%49.78%29.04%38.97%43.72%-
Other Operating Expenses37.79M6.49M19.83M-3.07M-18.85M-22.98M-12.2M-21.52M-111.54M-4M
Operating Income
-42.57M▲ 0%
-3.95M▲ 90.7%
6.26M▲ 258.3%
-811K▼ 113.0%
-55.11M▼ 6695.3%
-61.39M▼ 11.4%
-113.44M▼ 84.8%
-82.09M▲ 27.6%
13.33M▲ 116.2%
-74.83M▲ 0%
Operating Margin %-45.26%-3.76%5.54%-0.64%-49.95%-17.64%-31.4%-53.4%7.86%-41.59%
Operating Income Growth %-113.54%90.71%258.35%-112.95%-6695.31%-11.4%-84.79%27.64%116.24%-
EBITDA-31.3M7.19M13.09M7.72M-45.31M-47.11M-92.41M-64.5M32.92M-66.36M
EBITDA Margin %-33.27%6.83%11.58%6.12%-41.07%-13.53%-25.58%-41.96%19.41%-36.89%
EBITDA Growth %-268.57%122.96%82.12%-41.01%-686.85%-3.97%-96.15%30.2%151.03%-499.63%
D&A (Non-Cash Add-back)11.27M11.14M6.83M8.53M9.8M14.28M21.04M17.58M19.59M305K
EBIT-42.74M-7.5M7.14M1.76M-54.56M-53.02M-125.76M-75.3M12.5M-71.86M
Net Interest Income-5.8M-4.99M-3.61M-2.43M-10.62M-16.71M-18.79M-22.11M-21.62M-20.61M
Interest Income290K72K178K199K119K249K260K1.21M2.36M2.92M
Interest Expense6.09M5.06M3.79M2.63M10.74M16.96M19.05M23.32M23.98M23.53M
Other Income/Expense-6.26M-8.61M-2.91M-59K-10.18M-8.59M-31.37M-16.54M-24.82M-20.56M
Pretax Income
-48.83M▲ 0%
-12.56M▲ 74.3%
3.35M▲ 126.7%
-870K▼ 126.0%
-65.3M▼ 7406.0%
-69.98M▼ 7.2%
-144.81M▼ 106.9%
-98.63M▲ 31.9%
-11.49M▲ 88.4%
-95.39M▲ 0%
Pretax Margin %-51.91%-11.93%2.96%-0.69%-59.19%-20.1%-40.08%-64.16%-6.77%-53.02%
Income Tax356K-1.08M88K874K-909K3.45M-1.54M2.8M761K6.77M
Effective Tax Rate %-0.73%8.58%2.63%-100.46%1.39%-4.92%1.06%-2.84%-6.63%-7.1%
Net Income
-49.18M▲ 0%
-11.48M▲ 76.7%
3.26M▲ 128.4%
-1.74M▼ 153.4%
-64.39M▼ 3592.3%
-73.42M▼ 14.0%
-143.28M▼ 95.1%
-101.43M▲ 29.2%
-12.25M▲ 87.9%
-102.16M▲ 0%
Net Margin %-52.29%-10.9%2.89%-1.38%-58.37%-21.09%-39.66%-65.99%-7.22%-56.78%
Net Income Growth %-138.56%76.66%128.43%-153.43%-3592.26%-14.03%-95.14%29.21%87.93%-1277.19%
Net Income (Continuing)-49.18M-11.48M2.14M-1.74M-64.39M-73.42M-143.28M-101.43M-12.25M-102.16M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)
-1.32▲ 0%
-0.30▲ 77.3%
0.08▲ 126.7%
-0.04▼ 147.5%
-1.42▼ 3636.8%
-1.50▼ 5.6%
-2.48▼ 65.3%
-1.46▲ 41.1%
-0.17▲ 88.4%
-1.19▲ 0%
EPS Growth %-135.71%77.27%126.67%-147.5%-3636.84%-5.63%-65.33%41.13%88.36%-907.69%
EPS (Basic)-1.32-0.300.08-0.04-1.42-1.50-2.48-1.46-0.17-
Diluted Shares Outstanding37.33M38.72M40.8M45.87M45.38M48.81M57.74M69.31M70.26M85.87M
Basic Shares Outstanding37.33M38.27M40.26M45.87M45.38M48.81M57.74M69.47M70.26M85.87M
Dividend Payout Ratio----------

VALN Balance Sheet

Valneva SE (VALN) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Total Current Assets91.2M83.45M125.97M129.16M308.43M585.83M424.66M262.82M299.01M268.33M
Cash & Short-Term Investments35.27M33.55M77.08M64.44M204.39M346.64M289.43M126.08M168.27M143.46M
Cash Only35.27M33.55M77.08M64.44M204.39M346.64M289.43M126.08M168.27M143.46M
Short-Term Investments0000000000
Accounts Receivable16.91M17.62M11.26M24.03M19.23M44.01M23.91M41.65M35.2M20.08M
Days Sales Outstanding65.6361.0936.3669.563.6346.1524.1698.8975.7857.28
Inventory22.7M19.93M22.73M25.77M26.93M124.1M35.1M44.47M53.66M64.29M
Days Inventory Outstanding192.35158.22191188.26181.03241.0439.49160.89198.78224.05
Other Current Assets9.4M7.84M10.26M14.92M57.83M71.04M76.21M50.63M41.87M40.5M
Total Non-Current Assets115.69M105.89M103.93M135.56M140.74M231.52M196.69M197.24M201.02M179.9M
Property, Plant & Equipment39.04M38.37M38M69.34M78.15M173.83M154.04M156.59M158.12M142.07M
Fixed Asset Turnover2.41x2.74x2.97x1.82x1.41x2.00x2.35x0.98x1.07x1.20x
Goodwill0000000000
Intangible Assets58.96M48.47M44.89M41.81M35.41M32.7M28.71M25.57M25.26M23.15M
Long-Term Investments426K335K1.12M2.26M2.13M2.12M0000
Other Non-Current Assets17.69M17.03M17.23M17.16M19.47M19.28M8.3M8.49M8.04M32.44M
Total Assets
206.88M▲ 0%
189.34M▼ 8.5%
229.91M▲ 21.4%
264.72M▲ 15.1%
449.16M▲ 69.7%
817.35M▲ 82.0%
621.34M▼ 24.0%
460.06M▼ 26.0%
500.03M▲ 8.7%
448.23M▲ 0%
Asset Turnover0.45x0.56x0.49x0.48x0.25x0.43x0.58x0.33x0.34x0.38x
Asset Growth %-24.82%-8.48%21.42%15.14%69.67%81.97%-23.98%-25.96%8.69%-9.51%
Total Current Liabilities38.89M37.67M42.95M41.3M175.87M368.98M277.39M158.86M114.58M150.48M
Accounts Payable1.99M5.26M9.18M8.87M24.9M16.04M14.51M17.56M12.64M30.12M
Days Payables Outstanding16.8841.7477.1164.78167.3631.1416.3263.5546.8270.8
Short-Term Debt20.11M16.54M16.66M2M6.99M7.11M11.58M44.08M20.85M58.83M
Deferred Revenue (Current)001.68M694K89.58M124.02M9.41M5.7M3.01M7.7M
Other Current Liabilities7.67M7.48M6.03M13.22M35.53M159.37M184.01M55.88M44.59M39.44M
Current Ratio2.35x2.22x2.93x3.13x1.75x1.59x1.53x1.65x2.61x2.61x
Quick Ratio1.76x1.69x2.40x2.50x1.60x1.25x1.40x1.37x2.14x2.14x
Cash Conversion Cycle241.1177.57150.25192.9877.31256.0447.33196.23227.73210.53
Total Non-Current Liabilities67.94M59M43.78M88.27M195.87M277.79M124.15M172.95M204.2M147.27M
Long-Term Debt34.02M27.43M14.27M24.32M46.38M50.73M87.23M132.77M166.52M108.89M
Capital Lease Obligations27.52M26.66M25.8M56.59M49.39M53.69M28.16M29.09M26.43M105.04M
Deferred Tax Liabilities65K65K00412K1.29M694K3.64M4.16M16.28M
Other Non-Current Liabilities6.33M-64K655K6.63M99.63M167.35M8.07M7.46M7.08M32.23M
Total Liabilities106.83M96.67M86.72M129.57M371.74M646.77M401.55M331.81M318.78M297.75M
Total Debt82.5M71.5M57.6M85.22M105.45M114.66M152.38M208.82M216.31M195.84M
Net Debt47.23M37.95M-19.48M20.78M-98.94M-231.99M-137.05M82.74M48.04M52.38M
Debt / Equity0.82x0.77x0.40x0.63x1.36x0.67x0.69x1.63x1.19x1.19x
Debt / EBITDA-9.95x4.40x11.04x----6.57x-2.95x
Net Debt / EBITDA-5.28x-1.49x2.69x----1.46x1.46x
Interest Coverage-6.99x-0.78x1.65x-0.31x-5.13x-3.62x-5.95x-3.52x0.56x-3.05x
Total Equity
100.05M▲ 0%
92.67M▼ 7.4%
143.19M▲ 54.5%
135.15M▼ 5.6%
77.42M▼ 42.7%
170.58M▲ 120.3%
219.8M▲ 28.9%
128.25M▼ 41.7%
181.25M▲ 41.3%
150.48M▲ 0%
Equity Growth %-30.68%-7.38%54.51%-5.61%-42.72%120.33%28.85%-41.65%41.33%5.68%
Book Value per Share2.682.393.512.951.713.493.811.852.581.75
Total Shareholders' Equity100.05M92.67M143.19M135.15M77.42M170.58M219.8M128.25M181.25M150.48M
Common Stock11.64M11.64M13.64M13.64M13.65M15.79M20.75M20.84M24.38M25.78M
Retained Earnings-164.52M-171.9M-168.17M-169.16M-233.55M-306.97M-450.25M-551.68M-563.93M-629.1M
Treasury Stock-1.01M-1.11M0000-645K-645K-645K0
Accumulated OCI-35.74M-34.27M045.76M52.34M52.51M55.25M65.73M40.15M81.38M
Minority Interest0000000000

VALN Cash Flow Statement

Valneva SE (VALN) cash flow — operating, investing & free cash flow history

Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Cash from Operations6.5M12.83M16.31M5.53M137.74M76.9M-245.34M-202.74M-67.22M-67.22M
Operating CF Margin %6.92%12.18%14.43%4.38%124.85%22.09%-67.91%-131.9%-39.64%-
Operating CF Growth %126.73%97.22%27.1%-66.09%2391.19%-44.17%-419.04%17.36%66.85%216.02%
Net Income-49.18M-11.48M3.26M-1.74M-64.39M-73.42M-143.28M-101.43M-12.25M-102.16M
Depreciation & Amortization11.27M11.14M6.83M8.61M9.8M14.28M21.04M17.58M19.59M0
Stock-Based Compensation1.43M811K1.89M2.55M6.33M14.51M-8.66M5.11M7.97M0
Deferred Taxes357K-1.08M88K874K-909K3.45M-1.54M2.8M761K0
Other Non-Cash Items40.97M10.38M1.25M-1.76M20.7M81.96M33.07M18.25M-71.72M57.37M
Working Capital Changes1.67M3.06M2.99M-3M166.21M36.13M-145.98M-145.06M-11.57M25.93M
Change in Receivables2.36M597K4.34M-17.28M-24.02M-21.35M12.4M-2.85M15.71M0
Change in Inventory2.95M1.06M-2.79M-2.42M-4.2M-92.37M84.22M-9.16M-6.8M0
Change in Payables02.54M013.01M6.54M35.24M-14.05M-17.4M00
Cash from Investing14.89M-4.06M-2.92M-10.69M-19.34M-93.12M-29.05M-20.59M76.92M3.24M
Capital Expenditures-3.68M-4.04M-3.17M-10.88M-19.47M-93.17M-29.32M-14.23M-13.87M-7.19M
CapEx % of Revenue3.91%3.84%2.81%8.62%17.65%26.77%8.12%9.26%8.18%-
Acquisitions15.28M076K0008K-10.95M00
Investments----------
Other Investing3.29M72K254K199K131K55K260K4.6M90.78M10.44M
Cash from Financing-26.79M-10.44M30.95M-7.7M21.74M154.5M215.12M63.08M30.68M4.15M
Debt Issued (Net)-23.33M-5.31M-14.15M-2.61M26.16M-3.9M34.49M75.89M-6.49M-2.49M
Equity Issued (Net)1000K-147K1000K-1000K290K1000K1000K-240K1000K679K
Dividends Paid0000000000
Share Repurchases0-147K-23K-2.48M000-240K0-321K
Other Financing-10.93M-4.98M-4.17M-2.62M-4.71M-8.42M-9.21M-12.57M-19.97M853K
Net Change in Cash
-6.64M▲ 0%
-1.72M▲ 74.1%
43.54M▲ 2628.4%
-12.64M▼ 129.0%
140M▲ 1207.1%
142.29M▲ 1.6%
-57.21M▼ 140.2%
-160.45M▼ 180.5%
42.19M▲ 126.3%
-12.87M▲ 0%
Free Cash Flow
2.82M▲ 0%
8.79M▲ 211.4%
13.13M▲ 49.4%
-5.36M▼ 140.8%
118.27M▲ 2308.5%
-16.27M▼ 113.8%
-274.67M▼ 1588.2%
-217.06M▲ 21.0%
-83.66M▲ 61.5%
-26.11M▲ 0%
FCF Margin %3%8.35%11.62%-4.24%107.2%-4.67%-76.02%-141.21%-49.34%-14.52%
FCF Growth %110.46%211.41%49.41%-140.77%2308.53%-113.76%-1588.17%20.97%61.46%85.29%
FCF per Share0.080.230.32-0.122.61-0.33-4.76-3.13-1.19-1.19
FCF Conversion (FCF/Net Income)-0.13x-1.12x5.00x-3.17x-2.14x-1.05x1.71x2.00x5.49x0.26x
Interest Paid0000000000
Taxes Paid0000000000

VALN Key Ratios

Valneva SE (VALN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201620172018201920202021202220232024TTM
Return on Equity (ROE)-40.25%-11.92%2.77%-1.25%-60.58%-59.21%-73.41%-58.29%-7.91%-58.93%
Return on Invested Capital (ROIC)-18.14%-2.13%3.69%-0.43%-61.5%--797.32%-41.92%4.54%4.54%
Gross Margin54.2%56.33%61.58%60.4%50.78%46.01%10.2%34.37%41.89%45.36%
Net Margin-52.29%-10.9%2.89%-1.38%-58.37%-21.09%-39.66%-65.99%-7.22%-56.78%
Debt / Equity0.82x0.77x0.40x0.63x1.36x0.67x0.69x1.63x1.19x1.19x
Interest Coverage-6.99x-0.78x1.65x-0.31x-5.13x-3.62x-5.95x-3.52x0.56x-3.05x
FCF Conversion-0.13x-1.12x5.00x-3.17x-2.14x-1.05x1.71x2.00x5.49x0.26x
Revenue Growth20.04%11.94%7.35%11.64%-12.58%215.52%3.8%-57.46%10.32%13.48%

VALN Frequently Asked Questions

Valneva SE (VALN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Valneva SE (VALN) reported $179.9M in revenue for fiscal year 2024. This represents a 5875% increase from $3.0M in 2005.

Valneva SE (VALN) grew revenue by 10.3% over the past year. This is steady growth.

Valneva SE (VALN) reported a net loss of $102.2M for fiscal year 2024.

Dividend & Returns

Valneva SE (VALN) has a return on equity (ROE) of -7.9%. Negative ROE indicates the company is unprofitable.

Valneva SE (VALN) had negative free cash flow of $26.1M in fiscal year 2024, likely due to heavy capital investments.

Explore More VALN

Valneva SE (VALN) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.